Zanipine

 
 

Zanipine is a new antipsychotic designed to manage the negative effects of mental anguish. Used only in cases where a diagnosis is difficult to distinguish, it has often been called revolutionary because of its relatively limited side effects. Its research has been funded and backed by a group of companies looking to change the face of healthcare for the better including Tatio.

According to Dr Johnson MRCPsych, one of the UK's leading specialists in mental illness; "Zanipine has been hugely successful in patients presenting with 'non-traditional' symptoms. Its creation denotes a key improvement in their outlook."